HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Phenylephrine Products Proliferate Due To Pseudoephedrine Restrictions

This article was originally published in The Tan Sheet

Executive Summary

The growing trend of limiting pseudoephedrine accessibility in stores is driving an expanding market for nasal decongestant alternatives containing phenylephrine

You may also be interested in...

Replacing Pseudoephedrine Easier Said Than Done, OTC Firms Find

Reformulating pseudoephedrine products has posed a greater challenge than expected for a number of firms, as passage of a federal bill restricting sale of the ingredient looms

Pseudoephedrine 2006 Sales To Decline 35%, Perrigo Projects

Perrigo's fiscal 2006 pseudoephedrine sales will decrease 35% to the $110 mil. to $120 mil. range, the company projected during a 2005 year-end and fourth quarter analysts call Sept. 7

Meth Bill Draft Offers Quicker Review of Pseudoephedrine Replacements

Cough/cold medications reformulated to exclude pseudoephedrine would receive expedited review by FDA under a provision included in a recent draft of the Combat Meth Act

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts